Researchers at the Salk Institute found that the experimental drug J147, which delayed or reversed Alzheimer's disease progression in mouse models, bonds with mitochondrial ATP synthase and alters the levels of ATP and other molecules to improve mitochondrial health and stability, resulting in the slowing and reversal of disease progression and aging effects. The findings in the journal Aging Cell suggest J147 may be effective in treating Alzheimer's and other aging-related diseases, researchers said.